GeneTex

  • Country / Location Selection

United States (US)

PD-L1 antibody

KO/KD Comparison Orthogonal Overexpression
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763
Anti-PD-L1 antibody used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX104763
Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763
Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

Cat. No. GTX104763

Reference 37
11

Host

 Rabbit

Clonality

 Polyclonal

Isotype

 IgG

Application

 WB, ICC/IF, IHC-P, IHC-Fr, FACS

Reactivity

 Human
Package
100 μl ($399),
25 μl ($169)
See all PD-L1 products
PRODUCT

Summary

PD-L1 antibody recognizes programmed death-ligand 1 (PD-L1) protein, also known as B7 homolog 1 (B7-H1) and cluster of differentiation 274 (CD274) protein. PD-L1 is found on various cancer cells and transduces immunosuppressive signals by binding to the programmed cell death protein 1 (PD-1) on effector T cells, thereby diminishing immune system attacks on malignant cells. Blocking the interaction between PD-L1 and PD-1 with PD-L1 antibodies is generating great clinical interest as a mode of immunotherapy against a number of cancers.

APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.
Application Recommended Dilution
WB 1:500-1:3000
ICC/IF 1:100-1:1000
IHC-P 1:100-1:1000
IHC-Fr Assay dependent
FACS Assay dependent
Not tested in other applications.

Calculated MW

33 kDa. ( Note )

Observed MW

50 kDa. The observed M.W. is based on the following publication. PMID: 23674495

Positive Control

MDA-MB-231 (24μg/ml Tunicamycin treatment for 16 hr) , MDA-MB-231 , A431(100 ng/mL IFN-gamma treatment for 48 hr)

PROPERTIES

Form

Liquid

Buffer

1XPBS, 1% BSA, 20% Glycerol (pH7)

Preservative

0.025% ProClin 300

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

Concentration

0.29 mg/ml (Please refer to the vial label for the specific concentration.)

Antigen Species

Human

Immunogen

Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human PD-L1. The exact sequence is proprietary.

Purification

Purified by antigen-affinity chromatography.

Conjugation

Unconjugated

RRID

AB_1240586

Note

For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.

TARGET

Synonyms

CD274 molecule , B7-H , B7H1 , PD-L1 , PDCD1L1 , PDCD1LG1 , PDL1

Cellular Localization

Isoform 1: Cell membrane; Single-pass type I membrane protein , Isoform 2: Endomembrane system; Single-pass type I membrane protein

Background

Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.

Database

Research Area

DATA IMAGES

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

KO/KD

Wild-type (WT) and PD-L1 knockout (KO) MDA-MB-231 cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with PD-L1 antibody (GTX104763) diluted at 1:4000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

Comparison Orthogonal

Untreated (–) and treated (+) A431 whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membranes were blotted with PD-L1 antibody (GTX104763) diluted at 1:1200 and competitor's antibody (CST#13684) diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.

*The competitor is not affiliated with GeneTex and does not endorse this product.

Anti-PD-L1 antibody used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX104763

GTX104763 ICC/IF Image

KO/KD

PD-L1 antibody detects PD-L1 protein at cell membrane by immunofluorescent analysis.
Sample: MDA-MB-231 cells were fixed in ice-cold MeOH for 5 min.
Green: PD-L1 stained by PD-L1 antibody (GTX104763) diluted at 1:500.
Blue: Fluoroshield with DAPI (GTX30920).

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

Various whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with PD-L1 antibody (GTX104763) diluted at 1:2000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

Various whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with PD-L1 antibody (GTX104763) diluted at 1:2000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

KO/KD

Non-transfected (–) and transfected (+) A431 whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with PD-L1 antibody (GTX104763) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

Overexpression

Various whole cell extracts were separated by 10% SDS-PAGE, and the membranes were blotted with PD-L1 antibody (GTX104763) diluted at 1:600 and with DDDDK tag antibody (GTX115043) diluted at 1:3000 to detect DDDDK-tagged PD-L2. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.

Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763

GTX104763 IHC-P Image

PD-L1 antibody detects PD-L1 protein at cell membrane by immunohistochemical analysis.
Sample: Paraffin-embedded human ovarian cancer.
PD-L1 stained by PD-L1 antibody (GTX104763) diluted at 1:4000.
Antigen Retrieval: Citrate buffer, pH 6.0, 15 min

Anti-PD-L1 antibody used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX104763

GTX104763 ICC/IF Image

PD-L1 antibody detects PD-L1 protein by immunofluorescent analysis.
Sample: MDA-MB-231 (left) and HeLa (right) cells were fixed in ice-cold MeOH for 5 min.
Green: PD-L1 stained by PD-L1 antibody (GTX104763) diluted at 1:500.
Blue: Hoechst 33342 staining.
Scale bar= 10 μm.

Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763

GTX104763 IHC-P Image

PD-L1 antibody detects PD-L1 proteinat cell membrane in human ovarian carcinoma by immunohistochemical analysis.
Sample: Paraffin-embedded human ovarian carcinoma.
PD-L1 antibody (GTX104763) diluted at 1:1000.

Antigen Retrieval: Citrate buffer, pH 6.0, 15 min

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

Orthogonal

Untreated (–) and treated (+) MDA-MB-231 whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with PD-L1 antibody (GTX104763) diluted at 1:1000.

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

Comparison

Various whole cell extracts (30 μg) were separated by 12% SDS-PAGE, and the membranes were blotted with PD-L1 antibody (GTX104763) diluted at 1:2000 and competitor's antibody (CST#13684) diluted by 1:500. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.
*The competitor is not affiliated with GeneTex and does not endorse this product.

Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763

GTX104763 IHC-P Image

Comparison

PD-L1 antibody detects PD-L1 protein at cell membrane in PD-L1 protein-expressing cell lines by immunohistochemical analysis. Antibodies: PD-L1 antibody (GTX104763) diluted at 1:1000, and competitor's antibody diluted at 1:50. Samples: Negative (-), low positive (+), intermediate positive (++) and strong positive (+++) cell line cores assessed using Quantitative Digital Pathology.
Antigen Retrieval: Citrate buffer, pH 6.0, 15 min
*The competitor is not affiliated with GeneTex and does not endorse this product.

Anti-PD-L1 antibody used in IHC (Paraffin sections) (IHC-P). GTX104763

GTX104763 IHC-P Image

Comparison

PD-L1 antibody detects PD-L1 protein at cell membrane in human ovarian carcinoma by immunohistochemical analysis. Antibodies: PD-L1 antibody (GTX104763) diluted at 1:1000, and competitor's antibody diluted at 1:50.
Antigen Retrieval: Citrate buffer, pH 6.0, 15 min
*The competitor is not affiliated with GeneTex and does not endorse this product.

Anti-PD-L1 antibody used in Western Blot (WB). GTX104763

GTX104763 WB Image

Overexpression

Non-transfected (–) and transfected (+) 293T whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with PD-L1 antibody (GTX104763) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.

REFERENCE

Application Reference

Wu Y et al. Nat Cancer 2023; 4 (3) : 382-400 Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.
Application : IHC-P
Reactivity : Human
Chung SY et al. Neoplasia 2023; 35 : 100856 A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer.
Application : WB
Reactivity : Human
Chung BS et al. Int J Mol Sci 2022; 23 (21) PD-L1 Expression in High-Risk Early-Stage Colorectal Cancer-Its Clinical and Biological Significance in Immune Microenvironment.
Application : ICC/IF
Reactivity : Human
Su KW et al. Cells 2022; 11 (19) Thyroid Hormone Induces Oral Cancer Growth via the PD-L1-Dependent Signaling Pathway.
Application : WB, ICC/IF
Reactivity : Human
You-Zhe Lin et al. Comput Struct Biotechnol J 2022; 20 : 241-251 miR-4759 suppresses breast cancer through immune checkpoint blockade.
Application : WB
Reactivity : Human
Show More +
Submit a Reference

REVIEW

PD-L1 antibody Cat. No. GTX104763

Rating
( Average 4.8 based on 11 users reviews)
Application
Western Blot(WB)
( Average 4.8 based on 11 users reviews)
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 24-Jul-2023
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the 2021 in Cancer Metab. PMID: 33608051
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 10-Aug-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Cancers (Basel) in 2019.PMID: 31835799
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 10-Aug-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Cancers (Basel) in 2019.PMID: 31835799
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 10-Aug-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Cancers (Basel) in 2019.PMID: 31835799
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 10-Aug-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Cancers (Basel) in 2019.PMID: 31835799
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 10-Aug-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Cancers (Basel) in 2019.PMID: 31905966
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 10-Aug-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Cancers (Basel) in 2019.PMID: 31905966
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 09-May-2021
Score :
Application Tested : WB
Sample Species : Hu
Sample : Huh7 cells
Amount used : 10 μg
Blocking : 5% skim milk in TBST, 27°C, 1Hr
Primary Antibody : 1:5000, 4°C, 12Hr
Secondary Antibody : GTX213110-01, 1:5000, 27°C, 2Hr
Lane Description : Two groups (regorafenib -/+) of whole cell extracts (10 μg) were separated by 12% SDS-PAGE, and the membrane was blotted with PD-L1 antibody (GTX104763) diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 18-Mar-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Nat Commun in 2020. PMID: 32245950
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 18-Mar-2021
Score :
Application Tested : WB
Sample Species : Hu
Figure Note : The data was peer reviewed and published in the journal Nat Commun in 2020. PMID: 32245950
Anti-PD-L1 antibody used in Western Blot (WB). GTX104763
Date : Anonymous submitted on 22-May-2017
Score :
Application Tested : WB
Sample Species : Hu
Sample : SK-LMS-1 cells
Amount used : 30 μg
Blocking : 3%BSA, 25°C, 0.5Hr
Primary Antibody : 1:1000, 4°C, 16Hr
Show More +
Submit a Review
Application Reference
Wu Y et al. Nat Cancer 2023; 4 (3):382-400 Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.
Application : IHC-P
Reactivity : Human
Chung SY et al. Neoplasia 2023; 35:100856 A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer.
Application : WB
Reactivity : Human
Chung BS et al. Int J Mol Sci 2022; 23 (21) PD-L1 Expression in High-Risk Early-Stage Colorectal Cancer-Its Clinical and Biological Significance in Immune Microenvironment.
Application : ICC/IF
Reactivity : Human
Su KW et al. Cells 2022; 11 (19) Thyroid Hormone Induces Oral Cancer Growth via the PD-L1-Dependent Signaling Pathway.
Application : WB, ICC/IF
Reactivity : Human
You-Zhe Lin et al. Comput Struct Biotechnol J 2022; 20:241-251 miR-4759 suppresses breast cancer through immune checkpoint blockade.
Application : WB
Reactivity : Human
Hung YH et al. Am J Cancer Res 2022; 12 (2):713-728 Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1.
Application : FACS
Reactivity : Human
Omenai SA et al. PLoS One 2022; 17 (2):e0263615 Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients.
Application : IHC-P
Reactivity : Human
Asrini R et al. Mol Clin Oncol 2022; 16 (2):42 Expression of programmed cell death ligand-1 protein in germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Application : IHC-P
Reactivity : Human
Lin YZ et al. Computational and Structural Biotechnology Journal 2022; 20:241-251 miR-4759 suppresses breast cancer through immune checkpoint blockade.
Application : WB
Reactivity : Human
Jesus Pacheco-Torres et al. Cancer Metab 2021; 9 (1):10 The PD-L1 metabolic interactome intersects with choline metabolism and inflammation.
Application : WB
Reactivity : Human
Li L et al. Pharmacological Research - Modern Chinese Medicine 2021; 1 A combination therapy of ingredients from TCM for the prevention and treatment of gastric cancer by targeting HER2/ PD-L1.
Li L et al. Cancer Sci 2021; 112 (5):1772-1784 Systematic insight into the active constituents and mechanism of Guiqi Baizhu for the treatment of gastric cancer.
Application : WB
Reactivity : Human
Tuminello S et al. Transl Lung Cancer Res 2020; 9 (4):1343-1360 PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis.
Qin G et al. Nat Commun 2020; 11 (1):1669 NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
Chou CW et al. Am J Cancer Res 2020; 10 (8):2621-2634 The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer.
Application : WB
Reactivity : Human
Huang TY et al. Cells 2020; 9 (8) NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Application : WB
Reactivity : Human
Kim D et al. J Clin Med 2020; 9 (5) Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder.
Application : IHC-P
Reactivity : Human
Lenouvel D et al. Oral Oncol 2020; 106:104722 Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis.
Gondhowiardjo SA et al. PLoS One 2020; 15 (3):e0230449 Tumor microenvironment predicts local tumor extensiveness in PD-L1 positive nasopharyngeal cancer.
Application : IHC-P
Reactivity : Human
Nguyen HD et al. Cancers (Basel) 2019; 11 (12) The α9 Nicotinic Acetylcholine Receptor Mediates Nicotine-Induced PD-L1 Expression and Regulates Melanoma Cell Proliferation and Migration.
Pan MR et al. Cancers (Basel) 2019; 12 (1) Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.
Application : WB
Reactivity : Human
Chan LC et al. J Clin Invest 2019; 130 IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.
Application : WB
Reactivity : Human
Polioudaki H et al. Cell Oncol (Dordr) 2019; (Epub) Nuclear localization of PD-L1: artifact or reality?
Application : WB
Reactivity : Human
Wei-faYang et al. Oral Oncology 2018; 86:81-90 The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Application : IHC-P
Reactivity : Human
Cha JH et al. Mol Cell 2018; 71 (4):606-620.e7 * promotes antitumor immunity via endoplasmic-reticulum-associated degradation of pd-l1.
Application : IHC-Fr
Reactivity : Human
Li CW et al. Cancer Cell 2018; 33 (2):187-201.e10 Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.
Application : WB
Reactivity : Human
Takeuchi M et al. Immunol Lett 2018; (Epub) Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
Application : WB
Reactivity : Human
Liu Z et al. Int J Clin Exp Pathol 2017; 10 (12):11754-11759 Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis.
Buisseret L et al. Oncoimmunology 2017; 6 (1):e1257452 Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.
Liu Z et al. lInt J Clin Exp Pathol 2017; 10 (12):11754-11759 Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis.
Application : IHC-P
Reactivity : Human
He B et al. Biomed Pharmacother 2017; 98:95-101 Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1.
Application : WB
Reactivity : Human
Lin PL et al. Eur J Cancer 2017; 85:95-105 An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Application : IHC-P
Reactivity : Human
Lin PL et al. Cancer Med 2017; (Epub) A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers.
Application : IHC-P
Reactivity : Human
Wang LT et al. Cancer Res 2017; (Epub) Intestine-specific homeobox gene ISX integrates interleukin-6 signaling, tryptophan catabolism and immune suppression.
Application : WB
Reactivity : Human
Buisseret L et al. OncoImmunology 2016; (Epub) Tumor Infiltrating Lymphocyte Composition, Organization and PD-1/PD-L1 Expression are Linked in Breast Cancer.
Reactivity : Human
Qing Y et al. Drug Des Devel Ther 2015; 9:901-9 Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer.
Reactivity : Human
Lin YM et al. PLoS One 2015; 10 (11):e0142656 High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.
Reactivity : Human
SDS
PBS.pdf
Glycerol.pdf
Proclin.pdf
Package List Price ($)
$ 399
$ 169